Jan ter Meulen, M.D., Ph.D.

Jan ter Meulen, M.D., Ph.D.

Dr. ter Meulen is Obsidian's Chief Scientific Officer. A veteran researcher in pharmaceutical, biotechnology and academic settings, Dr. ter Meulen brings more than 25 years of operational and strategic research experience to Obsidian. Previously, as Chief Scientific Officer of Immune Design, Seattle, he was responsible for devising and communicating the immuno-oncology research strategy of the company, building its pipeline, and participating in the IPO and later sale of Immune Design to Merck & Co. in 2019. Before Immune Design, Dr. ter Meulen was Head of Vaccine Basic Research at Merck Research Laboratories, where he had operational responsibility for the entire vaccine discovery pipeline, and before, Head of Antibody discovery at Crucell N.V., Leiden, The Netherlands. He has held appointments at the German Cancer Research Center, Heidelberg, the Bernhard Nocht Institute of Tropical Medicine, Hamburg, and the Institute of Virology at the Philipps-University, Marburg, Germany. Dr. ter Meulen was an International Scholar of the Howard Hughes Medical Research Institute, and a consultant for scientific agencies in the US, UK, Germany, France, South Africa and for the European Commission.



< Back to Management